Navigation Links
ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
Date:4/30/2008

Company Will Seek Label for the Treatment of Ocular Itching Associated with

Allergic Conjunctivitis

IRVINE, Calif., April 30 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced positive results from the preliminary analysis of its second and final Bepreve(TM) (bepotastine ophthalmic solution) Phase III clinical study. The U.S. multi-center conjunctival allergen challenge (CAC) study evaluated the onset and duration of effect of two Bepreve concentrations in 130 patients with a history of ocular allergies. Both concentrations demonstrated highly statistically significant reductions in the primary study endpoint of ocular itching. In addition, both concentrations produced highly statistically significant effects on the rapidity of response and in the secondary endpoints measuring additional signs and symptoms of ocular allergy, as well as improvement in total nasal symptoms. There were no serious ocular adverse events reported in patients dosed with Bepreve.

The Phase III study was a multi-center, double-masked, placebo-controlled study. It was designed to evaluate the onset and duration of effect of Bepreve in two concentrations and in two dosing schedules, once-daily and twice-daily. Of the 130 patients enrolled, 117 completed the study. Patients were randomized 1:1:1 to receive one of two concentrations of Bepreve. They were evaluated on 3 separate visits for their response to the dose administered, which would allow for the determination of the time to onset, response at 8 hours and at 16 hours. Both statistical significance and degree of clinical response, were measured. The strongest clinical effect achieved was with twice-daily dosing of either concentration. Furt
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
2. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
3. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
4. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
5. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
6. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
7. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
8. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
9. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Sanofi (EURONEXT: SAN and NYSE: SNY ) announced ... , examining the selective JAK2 inhibitor SAR302503 for myelofibrosis ... The primary endpoint assessed the proportion of patients achieving ... in previous trials, the most common adverse events were ... presented at an upcoming medical congress. ...
(Date:5/17/2013)... Mass. , May 17, 2013  Boston Scientific ... participate at the annual EuroPCR Scientific Program May 21-24 ... are pleased to present a particularly rich and diversified ... Keith Dawkins , M.D., global chief medical ... trials will be presented, including the NG PROMUS trial, ...
(Date:5/16/2013)... 16, 2013  PTC Therapeutics, Inc., today announced that ... with the U.S. Securities and Exchange Commission ("SEC") relating ... stock. The number of shares to be offered and ... determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) ... joint book-running managers for the offering. Cowen and Company ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
... Conn. , May 14 Zargis Medical Corp., ... today announced that its Zargis Cardioscan device and the compatible ... of a Gold Award on April 29th at ... Channel in New York City . The prestigious Gold ...
... , Germany , May 14, 2010 On ... international user meeting of endoscopic,spinal surgery in Veenhuizen/Niederlande. Besides the ten ... Europe , the United States ,and other countries are expected ... will be opened with a keynote lecture of,Prof. Dr. Gerbrand ...
Cached Medicine Technology:Zargis Medical Strikes Gold at 2010 Edison Awards 2joimax(R) Holds the First International TESSYS(R) User Meeting in Veenhuizen, The Netherlands, and Announces the Launch of Various New Products for Endoscopic Spinal Surgery 2
(Date:5/18/2013)... Angeles, California (PRWEB) May 18, 2013 Online ... to be Rolex watch owners at a fraction ... collection of luxury timepieces in the world, buyers are urged ... As compared to buying a Rolex watch from a brick-and-mortar ... pre owned Rolex watches priced at unbelievable rates. Although ...
(Date:5/18/2013)... Dennis Thompson HealthDay Reporter , , FRIDAY, May ... unveils the latest edition of what is considered the ... its many changes continues. "This is unprecedented, the ... Jeffrey Lieberman, president-elect of the American Psychiatric Association (APA). ... what it is. You have to evaluate it and ...
(Date:5/18/2013)... a few extra cups of coffee each month might ... known as primary sclerosing cholangitis (PSC), a new study ... Minn., found that drinking coffee was associated with a ... to cirrhosis of the liver, liver failure and biliary ... relationship. "While rare, PSC has extremely detrimental ...
(Date:5/18/2013)... 2013) The use of a smartphone application ... to new research presented today at Digestive Disease ... in advance of the procedure, includes dietary restrictions ... taken at strict intervals. The better the preparation, ... cancer and precancerous polyps in the colon. The ...
(Date:5/18/2013)... -- Regular consumption of coffee is associated with ... an autoimmune liver disease, Mayo Clinic research shows. ... Disease Week 2013 conference in Orlando, Fla. ... bile ducts that results in inflammation and subsequent ... liver, liver failure and biliary cancer. , "While ...
Breaking Medicine News(10 mins):Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 2Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 2Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 4Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2Health News:New smartphone application improves colonoscopy preparation 2
... confirms that hormone replacement therapy (HRT) should not be prescribed ... help prevent chronic conditions such as heart disease . ... safe short term treatment for younger women in early menopause ... ,In 2002, the Womens Health Initiative (WHI) trial found that ...
... have, the slower you age . ,Researchers at ... moles in a study of 1,800 twins, at the Twin Research Unit ... the more likely their DNA was to have the properties to fight ... in spite of the fact that moles are linked with ...
... 13 million kilograms of antibiotics are used to raise ... are used for growth advancement and disease prevention ... up as manure, which is commonly applied to agricultural ... on manure-altered soils are exposed to antibiotics. , ...
... Thiruvananthapuram Zoo has barred the entry of visitors for a week ... reportedly lost its entire stock of Indian gaur (Bos Gaurus) -- ... the week gone by. ,It was confirmed last ... the death of animals. ,The zoo was being ...
... to a particular variety of sugar present on the surface ... are regarded as mindless killers. White blood cells (WBC) form ... our internal body. They protect our body from various kinds ... wiping out any intruder that invades the body. A new ...
... she feared that her recent miscarriage was god's way of punishing ... lost her baby when she was three months pregnant, said that ... of this year, she thought she would never recover after losing ... is all this happening?' I thought it was God's punishment for ...
Cached Medicine News:Health News:Study Confirms No HRT Benefit for Older Women 2Health News:Study Confirms No HRT Benefit for Older Women 3Health News:Dotted All Over? - Count Yourself Lucky 2Health News:Contamination of the Environment by Antibiotics Fed to Livestock 2Health News:WBC Selective About Sugar 2
... The intra-operative MR system ... intra-operative tool for radiologists ... goal of the system ... valuable adjunct to standard ...
... By combining intra-operative ultrasound ... Medtronic Surgical Navigation Technologies ... product called SonoNav Intra-operative ... built on the high ...
... two-component fibrin sealant vapor heated ... commercially available fibrin sealant in ... are used for two specific ... to seal tissue. Both of ...
... With Plasmaseal's Proteus device the two ... blood is injected into Proteus' single use ... action base unit. The operator touches a ... plasma is separated by centrifugation. Then the ...
Medicine Products: